← ANALYST RATINGS · TIPRANKS
Halozyme (HALO): analyst forecast and price target
Analyst consensus
Moderate Buy5 Buy2 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $106, the highest $130, the lowest $78.00. The average is −13.1% from the last price of $122.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $130 | Buy | +6.7% | Reiterated | 15.10.26on TipRanks 09:10 | +3.7%next day +1.4% | ↗ |
| Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% | TD Cowen | $105 → $130+23.8% | Buy | +6.7% | Assigned | 13.10.26on TipRanks 09:00 | −1.3%next day +7.6% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $70.00 → $78.00+11.4% | Hold | −36.0% | Assigned | 08.10.26on TipRanks 07:45 | −0.4%next day −0.1% · 5 days +10.9% | ↗ |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | $110 | Buy | −9.7% | Reiterated | 07.10.26on TipRanks Oct 8 05:16 | +1.2%next day −0.4% · 5 days +6.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $126 → $129+2.4% | Buy | +5.9% | Reiterated | 23.09.26on TipRanks Sep 22 21:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $127 → $129+1.6% | Buy | +5.9% | Reiterated | 23.09.26on TipRanks Sep 22 21:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $127 | Buy | +4.2% | Reiterated | 23.09.26on TipRanks Sep 22 21:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $124 → $126+1.6% | Buy | +3.4% | Reiterated | 23.09.26on TipRanks Sep 22 21:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $128 → $129+0.8% | Buy | +5.9% | Reiterated | 23.09.26on TipRanks Sep 22 21:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $127 → $126−0.8% | Buy | +3.4% | Reiterated | 23.09.26on TipRanks Sep 22 21:05 | — | |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $93.00 → $105+12.9% | Buy | −13.8% | Assigned | 07.08.26on TipRanks 08:20 | +19.6%next day −0.5% · 5 days −4.7% | ↗ |
| Jason Butler★★★★★★★★★★#412 · hits 51% · avg +18.3% | Citizens JMP | $92.00 → $93.00+1.1% | Buy | −23.7% | Reiterated | 07.08.26on TipRanks 06:20 | +19.6%next day −0.5% · 5 days −4.7% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $75.00 → $95.00+26.7% | Hold | −22.0% | Assigned | 07.08.26on TipRanks 05:30 | +19.6%next day −0.5% · 5 days −4.7% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $57.00 | Sell | −53.2% | Reiterated | 14.06.26on TipRanks Jun 15 07:50 | +0.8%next day −1.7% · 5 days +0.2% | ↗ |
| Unknown Analyst | J.P. Morgan | $70.00 | Hold | −42.5% | Reiterated | 20.05.26on TipRanks May 21 21:03 | −0.7%next day −0.9% · 5 days −3.0% | ↗ |
| Robert Wasserman★★★★★★★★★★#2200 · hits 44% · avg +9.2% | Benchmark Co. | $75.00 → $90.00+20.0% | Buy | −26.1% | Reiterated | 19.02.26on TipRanks 08:40 | −1.4%next day −2.2% · 5 days −4.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Halozyme
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 07.10.26: target $104 at a price of $110 (−5.4%); now: $106 at $122 (−13.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Buy | 8 | 10 | 7 | 9 | 8 | 12 |
| Hold | 1 | 2 | 2 | 2 | 1 | 2 |
| Sell | 0 | 1 | 1 | 1 | 0 | 0 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.30 (from $2.00 to $2.37). Last quarter: $2.28.
Sales
Next quarter’s sales estimate — $491M (from $482M to $496M). Last quarter: $481M.
Best top-analyst consensus in the sector · Healthcare
About Halozyme
- CEO: Helen I. Torley
- Employees: 423
- 12390 El Camino Real, San Diego, CA, 92130, US
- www.halozyme.com
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with re
Data from the stock’s TipRanks forecast page, read 29 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗